NFKB1 and non-small cell lung carcinoma: Some studies highlight the role of NF-κB in promoting resistance to EGFRi treatment, showing that silencing specific genes related to the NF-κB and Fas death receptor signaling pathways can sensitize NSCLC cells to erlotinib[212,213].